Compare Stocks

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
$0.29
$0.15
$0.84
$10.93M1.3160,047 shs1.27 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.

Get This Free Report

Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.00%0.00%0.00%0.00%-75.47%

MarketRank™

CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
0.7181 of 5 stars
3.50.00.00.00.01.70.0

Analyst Ratings

CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
3.00
Buy$2.75∞ Upside

Current Analyst Ratings

Sales & Book Value

CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/A$0.32 per shareN/A

Profitability & Earnings

CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
-$7.60M-$0.09N/AN/AN/AN/A-42.68%-35.17%N/A

Dividends

CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/AN/AN/AN/AN/A

Debt

CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
N/A
9.57
9.57

Ownership

Institutional Ownership

CompanyInstitutional Ownership
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
12.38%

Insider Ownership

CompanyInsider Ownership
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
33.10%

Miscellaneous

CompanyEmployeesShares OutstandingFree FloatOptionable
Medicenna Therapeutics Corp. stock logo
MDNA
Medicenna Therapeutics
1669.64 million46.59 millionNot Optionable

SCLP and MDNA Headlines

SourceHeadline
Medicenna reports advancement in cancer immunotherapyMedicenna reports advancement in cancer immunotherapy
investing.com - April 11 at 9:15 AM
Medicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor ConferenceMedicenna to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
finance.yahoo.com - April 4 at 7:59 AM
Medicenna Therapeutics Corp MDNAMedicenna Therapeutics Corp MDNA
morningstar.com - March 1 at 2:01 AM
Medicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate UpdateMedicenna Therapeutics Reports Third Quarter Fiscal 2024 Financial Results and Corporate Update
finance.yahoo.com - February 14 at 10:05 AM
Medicenna Announces Appointment of New AuditorMedicenna Announces Appointment of New Auditor
tmcnet.com - January 12 at 6:05 PM
Medicenna Announces Trading on the OTCQB Under the Symbol MDNAFMedicenna Announces Trading on the OTCQB Under the Symbol MDNAF
finance.yahoo.com - December 19 at 7:23 AM
MDNA.TO: Overall Survival Data from Phase 2b Trial of Bizaxofusp Presented at SNO 2023…MDNA.TO: Overall Survival Data from Phase 2b Trial of Bizaxofusp Presented at SNO 2023…
finance.yahoo.com - November 20 at 5:51 PM
Medicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational HighlightsMedicenna Therapeutics Reports Second Quarter Fiscal 2024 Financial Results and Operational Highlights
finance.yahoo.com - November 14 at 10:03 AM
MDNA.TO: Additional Confirmed PR in Phase 1/2 ABILITY Trial of MDNA11MDNA.TO: Additional Confirmed PR in Phase 1/2 ABILITY Trial of MDNA11
finance.yahoo.com - November 13 at 1:37 PM
Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Medicenna Announces Promising Single-Agent Response and Durability of MDNA11 in the Phase 1/2 ABILITY Study During Dose Escalation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
finance.yahoo.com - November 6 at 7:57 AM
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated ...Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated ...
enidnews.com - November 5 at 8:33 PM
Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)Medicenna Presents Preclinical Data on MDNA113, its Targeted Metalloprotease Activated SuperKine (T-MASK) at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
finance.yahoo.com - November 3 at 1:37 PM
Why Is Medicenna Therapeutics (MDNA) Stock Down Today?Why Is Medicenna Therapeutics (MDNA) Stock Down Today?
msn.com - October 30 at 9:46 AM
Medicenna shifts to Toronto state of mind as Nasdaq listing lapsesMedicenna shifts to Toronto state of mind as Nasdaq listing lapses
fiercebiotech.com - October 27 at 1:03 PM
Medicenna Announces Nasdaq Delisting and Cutback of Management TeamMedicenna Announces Nasdaq Delisting and Cutback of Management Team
finance.yahoo.com - October 27 at 8:02 AM
Medicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid TumorsMedicenna Therapeutics Doses First Patient in Phase 2 Monotherapy Dose Expansion Portion of the ABILITY Study Evaluating MDNA11 in Select Types of Solid Tumors
finance.yahoo.com - October 25 at 9:37 AM
Closing Bell: Medicenna Therapeutics Corp up on Thursday (MDNA)Closing Bell: Medicenna Therapeutics Corp up on Thursday (MDNA)
theglobeandmail.com - October 13 at 12:40 PM
Medicenna Therapeutics Names Humphrey Gardner CMOMedicenna Therapeutics Names Humphrey Gardner CMO
markets.businessinsider.com - October 10 at 8:13 AM
Medicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical OfficerMedicenna Therapeutics Appoints Humphrey Gardner, M.D., as Chief Medical Officer
finance.yahoo.com - October 10 at 8:13 AM
Medicenna Announces Results of Annual and Special Meeting of ShareholdersMedicenna Announces Results of Annual and Special Meeting of Shareholders
finance.yahoo.com - September 28 at 6:57 PM
Medicenna Therapeutics (TSE:MDNA) Price Target Decreased by 12.14% to 3.94Medicenna Therapeutics (TSE:MDNA) Price Target Decreased by 12.14% to 3.94
nasdaq.com - September 13 at 1:31 AM
Closing Bell: Medicenna Therapeutics Corp flat on Monday (MDNA)Closing Bell: Medicenna Therapeutics Corp flat on Monday (MDNA)
theglobeandmail.com - August 22 at 11:51 AM
MDNA: Commences Monotherapy Dose Expansion in Phase 1/2 ABILITY Trial…MDNA: Commences Monotherapy Dose Expansion in Phase 1/2 ABILITY Trial…
msn.com - August 15 at 4:46 PM
The Latest Analyst Ratings for Medicenna TherapeuticsThe Latest Analyst Ratings for Medicenna Therapeutics
markets.businessinsider.com - August 14 at 3:22 PM

New MarketBeat Followers Over Time

Company Descriptions

Medicenna Therapeutics logo

Medicenna Therapeutics

NASDAQ:MDNA
Medicenna Therapeutics Corp., an immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer and other diseases. It develops MDNA55, an interleukin- 4 (IL-4) EC for the treatment of recurrent glioblastoma, as well as for brain tumors. The company also develops MDNA11, an enhanced version of IL-2 to activate and proliferate the immune cells needed to fight cancer; MDNA209, an IL-2 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host disease; MDNA413, a dual IL-4/IL-13 antagonist to treat cancer immunotherapies; and MDNA132, an IL-13 Superkine for solid tumors. In addition, it provides BiSKITs platform to develop designer Superkines by fusing them to other proteins, antibodies, cytokines, or other Superkines. The company is headquartered in Toronto, Canada.